
    
      Primary:

      • To compare the ocular efficacy of Cationorm Pro® with that of VISMED® in patients with
      moderate to severe DED related to keratitis or keratoconjunctivitis after a 4-week treatment
      period (Day 28).

      Secondary:

      To compare the ocular efficacy of Cationorm Pro® with that of VISMED® in patients with
      moderate to severe DED related to keratitis or keratoconjunctivitis over a 12-week treatment
      period To evaluate the ocular tolerability and safety of Cationorm Pro® versus VISMED® in
      patients with moderate to severe DED related to keratitis or keratoconjunctivitis throughout
      the duration of treatment
    
  